What's Happening?
Xenetic Biosciences, a biopharmaceutical company, has announced positive preclinical data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The data demonstrates that DNase I significantly enhances CAR-T cell expansion, persistence,
and antitumor efficacy in aggressive hematologic cancer models. The findings suggest that DNase I can degrade immunosuppressive barriers like extracellular DNA and neutrophil extracellular traps (NETs), which are known to cause CAR-T cell exhaustion and persistence issues. The study showed improved CAR-T cell function and tumor control in preclinical models, supporting the potential of DNase I as an adjunctive therapy to improve outcomes in difficult-to-treat cancers.
Why It's Important?
The development of DNase I as an adjunctive therapy could significantly impact the treatment of aggressive hematologic cancers by enhancing the effectiveness of CAR-T cell therapies. This advancement addresses a critical challenge in cancer treatment, where immune suppression and therapeutic resistance often lead to treatment failure. By improving CAR-T cell persistence and reducing exhaustion, DNase I could lead to better patient outcomes and prolonged survival. This innovation could also pave the way for broader applications in other cancer types, potentially transforming the landscape of immuno-oncology therapies.
What's Next?
Xenetic Biosciences plans to continue the clinical development of DNase I as a combinatorial strategy to augment CAR-T cell therapies. The company aims to advance its systemic DNase program into clinical trials for pancreatic carcinoma and other solid tumors. The ongoing research and development efforts will focus on validating the preclinical findings in human trials, which could lead to new treatment protocols and improved therapeutic options for patients with difficult-to-treat cancers.
